Citations

Clear

1906 citation(s) found for "Yu, Frank".

Hearing loss and microstructural integrity of the brain in a dementia‐free older population
Croll, Pauline H. , Vernooij, Meike W. , Goedegebure, André , Rigters, Stephanie C. , Sharrett, A. Richey , Lin, Frank R. , Reid, Robert I. , Power, Melinda C. , Jong, Robert J. Baatenburg de , Mosley, Thomas H. , Groot, Marius de , Deal, Jennifer A.

Mayo Clinic

Alzheimer's & Dementia | August 2, 2020 | Volume: 16 | Issue: 11 | Pages: 1515-1523

10.1002/alz.12151 | PMID 32743902 Get It

AbstractIntroductionAs hearing loss has been identified as an important risk factor for dementia, we aimed to assess the association between hearing loss and microstructural integrity of the brain.MethodsA total of 1086 dementia‐free participants (mean age = 75.2 [standard deviation: 4.9], 61.4% female) of the population‐based Atherosclerosis Risk in Communities (ARIC) study underwent hearing assessment (2016–2017) and magnetic resonance imaging of the brain (2011–2013). Microstructural integrity was determined with diffusion tensor imaging. Multivariable linear regression was used to investigate associations between hearing loss and microstructural integrity of different brain regions and white matter (WM) tracts.ResultsHearing loss was associated with lower WM microstructural integrity in the temporal lobe, lower gray matter integrity of the hippocampus, and with lower WM microstructural integrity of the limbic tracts and the uncinate fasciculus.ConclusionOur results demonstrate that hearing loss is indepedently associated with lower microstructural integrity in brain regions that are important for different cognitive processes.
Revisit, Reform, and Redesign: A Novel Dissection Approach for Demonstrating Anatomy of the Orbit for Continuing Professional Development Education
Gavril, Diana L., Frank, Konstantin , Schenck, Thilo L., Pawlina, Wojciech, Lachman, Nirusha , Frank, Konstantin , Lachman, Nirusha , Cotofana, Sebastian

Mayo Clinic

Anatomical Sciences Education | July 30, 2020 | Volume: 14 | Issue: 4 | Pages: 505-512

10.1002/ase.2006 | PMID 32729168 Get It

Advanced postgraduate medical education for health‐care professionals is constantly evolving. Understanding facial anatomy and especially its vascular system is crucial when performing soft tissue filler injections to avoid adverse events including tissue loss or irreversible blindness. Standard anatomical resources often fall short of elucidating clinically relevant concepts in more highly specialized areas of interest. A novel dissection approach for demonstrating the anatomy of the lateral orbit was presented at scientific meetings to participants from dermatology, plastic surgery, and general practice. Results from the post‐course online survey (n = 52) were analyzed. The results of the survey reveal a high educational impact and a high clinical relevance of the novel dissection approach. In addition, the majority of respondents (97.7%; n = 51) felt that the exposed anatomical structure of the orbit and face improved their ability to safely perform cosmetic procedures on the face. More experienced respondents who had previously attended at least five cadaveric dissections were more likely to strongly agree that reviewing anatomy through this novel dissection approach increased their confidence in avoiding periorbital vascular danger zones. As minimally invasive outpatient procedures continue to evolve, practicing physicians and mid‐level providers often face the challenge of having to reconcile preexisting anatomical knowledge with new clinical practice. Skills required to navigate high impact anatomy include visualization of structures that form the navigational landscape and avoidance of key danger zones. The novel dissection approach to the lateral orbit reflects the increasing focus on revisiting, reforming, and redesigning anatomy for continuing professional development activities.
The consensus Immunoscore in phase 3 clinical trial (N0147) and impact on patient management decisions
Lanzi, Anastasia, Benson, Al B. , Sinicrope, Frank A. , Galon, Jérôme

Mayo Clinic

OncoImmunology | July 20, 2020 | Volume: 9 | Issue: 1 | Pages: No page available

10.1080/2162402x.2020.1796003 | PMID 32934890 Get It

Postoperative Critical Events Associated With Obstructive Sleep Apnea: Results From the Society of Anesthesia and Sleep Medicine Obstructive Sleep Apnea Registry
Bolden, Norman, Posner, Karen L. , Domino, Karen B. , Auckley, Dennis , Benumof, Jonathan L., Herway, Seth T., Hillman, David R. , Mincer, Shawn L., Overdyk, Frank J. , Warner, Lindsay L. , Samuels, David J., Weingarten, Toby N. , Chung, Frances

Mayo Clinic

Anesthesia & Analgesia | July 16, 2020 | Volume: 131 | Issue: 4 | Pages: 1032-1041

10.1213/ane.0000000000005005 | PMID 32925320 Get It

BACKGROUND: Obstructive sleep apnea (OSA) patients are at increased risk for pulmonary and cardiovascular complications; perioperative mortality risk is unclear. This report analyzes cases submitted to the OSA Death and Near Miss Registry, focusing on factors associated with poor outcomes after an OSA-related event. We hypothesized that more severe outcomes would be associated with OSA severity, less intense monitoring, and higher cumulative opioid doses. METHODS: Inclusion criteria were age ≥18 years, OSA diagnosed or suspected, event related to OSA, and event occurrence 1992 or later and <30 days postoperatively. Factors associated with death or brain damage versus other critical events were analyzed by tests of association and odds ratios (OR; 95% confidence intervals [CIs]). RESULTS: Sixty-six cases met inclusion criteria with known OSA diagnosed in 55 (83%). Patients were middle aged (mean = 53, standard deviation [SD] = 15 years), American Society of Anesthesiologists (ASA) III (59%, n = 38), and obese (mean body mass index [BMI] = 38, SD = 9 kg/m 2 ); most had inpatient (80%, n = 51) and elective (90%, n = 56) procedures with general anesthesia (88%, n = 58). Most events occurred on the ward (56%, n = 37), and 14 (21%) occurred at home. Most events (76%, n = 50) occurred within 24 hours of anesthesia end. Ninety-seven percent (n = 64) received opioids within the 24 hours before the event, and two-thirds (41 of 62) also received sedatives. Positive airway pressure devices and/or supplemental oxygen were in use at the time of critical events in 7.5% and 52% of cases, respectively. Sixty-five percent (n = 43) of patients died or had brain damage; 35% (n = 23) experienced other critical events. Continuous central respiratory monitoring was in use for 3 of 43 (7%) of cases where death or brain damage resulted. Death or brain damage was (1) less common when the event was witnessed than unwitnessed (OR = 0.036; 95% CI, 0.007–0.181; P < .001); (2) less common with supplemental oxygen in place (OR = 0.227; 95% CI, 0.070–0.740; P = .011); (3) less common with respiratory monitoring versus no monitoring (OR = 0.109; 95% CI, 0.031–0.384; P < .001); and (4) more common in patients who received both opioids and sedatives than opioids alone (OR = 4.133; 95% CI, 1.348–12.672; P = .011). No evidence for an association was observed between outcomes and OSA severity or cumulative opioid dose. CONCLUSIONS: Death and brain damage were more likely to occur with unwitnessed events, no supplemental oxygen, lack of respiratory monitoring, and coadministration of opioids and sedatives. It is important that efforts be directed at providing more effective monitoring for OSA patients following surgery, and clinicians consider the potentially dangerous effects of opioids and sedatives—especially when combined—when managing OSA patients postoperatively.
Clinical validation of the temporal lifting technique using soft tissue fillers
Hernandez, Claudia A, Freytag, David L., Gold, Michael H. , Pavicic, Tajana, Ascher, Benjamin, Almeida, Ada Trindade de , Fabi, Sabrina G. , Frank, Konstantin , Cotofana, Sebastian , Frank, Konstantin , Cotofana, Sebastian , Gold, Michael H , Pavicic, Tatjana , Green, Jeremy B.

Mayo Clinic

Journal of Cosmetic Dermatology | July 14, 2020 | Volume: 19 | Issue: 10 | Pages: 2529-2535

10.1111/jocd.13621 | PMID 32662554 Get It

AbstractBackgroundWhile the temporal lifting technique has gained increasing attention, there is a dearth of objective and reliable evidence of its effects.AimThe objective of the present study is to analyze the ability of the temporal lifting technique to reduce the midfacial volume by soft tissue repositioning and to achieve an improved pan‐facial appearance by targeting exclusively the subdermal plane of the posterior and superior temple with soft tissue fillers.MethodsA total of 12 patients (1 male and 11 females) with a mean age of 36.75 ± 6.6 years and a mean body mass index of 23.04 ± 1.3 kg/m2 were included in this prospective clinical single‐center interventional study. Injection‐related outcome was evaluated utilizing 3D skin vector displacement and surface volume analyses and scoring based on five different evaluators.ResultsThree months after the treatment, the global esthetic improvement scale rating showed an improved outcome (3.08) when evaluated by the independent observers, very improved outcome when evaluated by the treating physician (4.33), and exceptional improvement when rated by the patient (4.83). Temporal volume improved by 0.36 (P < .001), lower cheek fullness by 0.47 (P < .001), and jawline contouring by 0.51 (P < .001). No major adverse events were reported during the 3‐month observational period.ConclusionObjective outcome measures have provided evidence that by augmenting the posterior superior temple the volume of the middle face can be reduced and the contour of the jawline can be accentuated; this is due to the underlying fascial anatomy and the resulting soft tissue re‐position.
Discontinuation of Oxygen as a Clinical Outcome Measure in Pneumonia with Acute Respiratory Failure
Chalmers, Sarah , Frank, Ryan D. , Odeyemi, Yewande , Lal, Amos , Gajic, Ognjen

Mayo Clinic

A41. CRITICAL CARE: PREDICTING AND MEASURING OUTCOMES | July 8, 2020 | Volume: No volume available | Issue: No issue available | Pages: A1614-A1614

10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a1614 Get It

Effects of Losartan vs. Placebo on Pulmonary Biomarkers in HIV: A Randomized Comparison
Collins, Gary, Wendt, Christine , Rhame, Frank S., Rizza, Stacey A. , Zelalem, T., Liappis, Angelike P., Irini, S., MacDonald, David M. , Baker, Jason V. , Wolfson, Julian , Tracy, Russell P. , Deeks, Steven G. , Morse, Caryn G. , Kunisaki, Ken M.

Mayo Clinic

A108. HIV RELATED PNEUMONIA, TB, AND MYCOBACTERIAL INFECTIONS | July 7, 2020 | Volume: No volume available | Issue: No issue available | Pages: A2697-A2697

10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a2697 Get It

Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Pfister, David G. , Spencer, Sharon, Adelstein, David J. , Brizel, David M. , Busse, Paul M., Cmelak, Anthony J. , Eisele, David W. , Fenton, Moon J. , Foote, Robert L. , Galloway, Thomas J. , Gillison, Maura L. , Haddad, Robert I. , Hicks, Wesley L. , Hitchcock, Ying J. , Jimeno, Antonio , Leizman, Debra S., Maghami, Ellie, Mell, Loren K. , Mittal, Bharat B. , Pinto, Harlan A. , Rocco, James W. , Rodriguez, Cristina P. , Weber, Randal S. , Weinstein, Gregory S., Witek, Matthew E. , Worden, Frank , Yom, Sue S. , Zhen, Weining, Burns, Jennifer L. , Darlow, Susan, Brizel, David M , Haddad, Robert , Mittal, Bharat B , Yom, Sue S , Adkins, Douglas R. , Anzai, Yoshimi , Bruce, Justine Y. , Caudell, Jimmy J , Colevas, Alexander Dimitrios , Ridge, John Andrew , Shah, Jatin P.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | July 7, 2020 | Volume: 18 | Issue: 7 | Pages: 873-898

10.6004/jnccn.2020.0031 | PMID 32634781 Get It

Treatment is complex for patients with head and neck (H&N) cancers with specific site of disease, stage, and pathologic findings guiding treatment decision-making. Treatment planning for H&N cancers involves a multidisciplinary team of experts. This article describes supportive care recommendations in the NCCN Guidelines for Head and Neck Cancers, as well as the rationale supporting a new section on imaging recommendations for patients with H&N cancers. This article also describes updates to treatment recommendations for patients with very advanced H&N cancers and salivary gland tumors, specifically systemic therapy recommendations.
Combination of phosphodiesterase‐5‐inhibitors and beta blockers improves experimental portal hypertension and erectile dysfunction
Uschner, Frank Erhard , Glückert, Kathleen, Gnad, Thorsten , Schierwagen, Robert , Mandorfer, Mattias , Magdaleno, Fernando , Ortiz, Cristina , Schwarzkopf, Katharina , Kamath, Patrick S. , Alessandria, Carlo , Boesecke, Christoph , Pfeifer, Alexander , Reiberger, Thomas , Kreisel, Wolfgang , Sauerbruch, Tilman , Ferlitsch, Arnulf , Trebicka, Jonel , Klein, Sabine , Uschner, Frank E , Paternostro, Rafael , Gnad, Thorsten , Mandorfer, Mattias , Schwarzkopf, Katharina , Pfeifer, Alexander , Reiberger, Thomas , Kreisel, Wolfgang , Trebicka, Jonel

Mayo Clinic

Liver International | July 6, 2020 | Volume: 40 | Issue: 9 | Pages: 2228-2241

10.1111/liv.14586 | PMID 32627946 Get It

AbstractBackground & AimsPhosphodiesterase‐5 inhibitors (PDE‐5‐I) are used for treatment of erectile dysfunction (ED), which is common in patients with cirrhosis. They may improve portal hypertension (PH), but contradictory data on efficacy and side‐effects have been reported. Non‐selective beta blockers (NSBB) reduce portal pressure, but might aggravate ED. Thus, we evaluated the combination of PDE‐5‐I with NSBB and its impact on PH and ED in experimental cirrhosis.MethodsED was assessed in cirrhotic patients (n = 86) using standardized questionnaire. Experimental cirrhosis was induced by bile‐duct‐ligation or carbon‐tetrachloride intoxication in rats. Corpus cavernosum pressure – a surrogate of ED ‐, as well as systemic and portal haemodynamics, were measured in vivo and in situ after acute administration of udenafil alone or in combination with propranolol. mRNA and protein levels of PDE‐5 signalling were analysed using PCR and western Blot.ResultsED in humans was related to severity of liver disease and to NSBB treatment. PDE‐5 was mainly expressed in hepatic stellate cells and upregulated in human and experimental cirrhosis. Propranolol reduced corpus cavernosum pressure in cirrhotic rats and it was restored by udenafil. Even though udenafil treatment improved PH, it led to a reduction of mean arterial pressure. The combination of udenafil and propranolol reduced portal pressure and hepatic resistance without systemic side‐effects.ConclusionsED is common with advanced cirrhosis and concomitant NSBB treatment. The combination of PDE‐5‐I and NSBB improves ED and PH in experimental cirrhosis.
Ubrogepant does not induce latent sensitization in a preclinical model of medication overuse headache
Navratilova, Edita , Behravesh, Sasan , Oyarzo, Janice, Banerjee, Pradeep, Navratilova, Edita , Dodick, David W. , Porreca, Frank

Mayo Clinic

Cephalalgia | July 3, 2020 | Volume: 40 | Issue: 9 | Pages: 892-902

10.1177/0333102420938652 | PMID 32615788 Get It

Background Ubrogepant, a small-molecule calcitonin gene-related peptide receptor antagonist, was recently approved as an oral medication for the acute treatment of migraine. This study aimed to determine whether ubrogepant shows efficacy in a preclinical model of migraine-like pain and whether repeated oral administration of ubrogepant induces latent sensitization relevant to medication overuse headache in rats. Methods A “two-hit” priming model of medication overuse headache was used. Female Sprague-Dawley rats received six oral doses of sumatriptan 10 mg/kg over 2 weeks to induce latent sensitization (i.e. “priming”). Cutaneous allodynia was measured periodically over 20 days in the periorbital and hindpaw regions using von Frey filaments. The rats were then subjected to a 1-hour bright light stress challenge on two consecutive days. At the start of the second bright light stress exposure, oral sumatriptan 10 mg/kg, oral ubrogepant 25, 50, or 100 mg/kg, or vehicle was administered; thereafter, cephalic and hindpaw sensory thresholds were monitored hourly over 5 hours to determine the efficacy of ubrogepant in reversing bright light stress-induced cutaneous allodynia. A dose of ubrogepant effective in the medication overuse headache model (100 mg/kg) was then selected to determine if repeated administration would produce latent sensitization. Rats were administered six oral doses of ubrogepant 100 mg/kg, sumatriptan 10 mg/kg (positive control), or vehicle over 2 weeks, and cutaneous allodynia was evaluated regularly. Testing continued until mechanosensitivity returned to baseline levels. Rats were then challenged with bright light stress on days 20 and 21, and periorbital and hindpaw cutaneous allodynia was measured. On days 28 to 32, the same groups received a nitric oxide donor (sodium nitroprusside 3 mg/kg, i.p.), and cutaneous allodynia was assessed hourly over 5 hours. Results Sumatriptan elicited cutaneous allodynia in both cephalic and hindpaw regions; cutaneous allodynia resolved to baseline levels after cessation of drug administration (14 days). Sumatriptan priming resulted in generalized and delayed cutaneous allodynia, evoked by either bright light stress (day 21) or nitric oxide donor (day 28). Ubrogepant dose-dependently blocked both stress- and nitric oxide donor-induced cephalic and hindpaw allodynia in the sumatriptan-induced medication overuse headache model with a 50% effective dose of ∼50 mg/kg. Unlike sumatriptan, ubrogepant 100 mg/kg in repeated effective doses did not produce cutaneous allodynia or latent sensitization. Conclusions Both ubrogepant and sumatriptan demonstrated efficacy as acute medications for stress- and nitric oxide donor-evoked cephalic allodynia in a preclinical model of medication overuse headache, consistent with their clinical efficacy in the acute treatment of migraine. However, in contrast to sumatriptan, repeated treatment with ubrogepant did not induce cutaneous allodynia or latent sensitization. These studies suggest ubrogepant may offer an effective acute treatment of migraine without risk of medication overuse headache. Trial Registration Number: Not applicable